Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Circulation (New York, N.Y.) Ročník 137; číslo 4; s. 338
Hlavní autori:	Bonaca, Marc P, Nault, Patrice, Giugliano, Robert P, Keech, Anthony C, Pineda, Armando Lira, Kanevsky, Estella, Kuder, Julia, Murphy, Sabina A, Jukema, J Wouter, Lewis, Basil S, Tokgozoglu, Lale, Somaratne, Ransi, Sever, Peter S, Pedersen, Terje R, Sabatine, Marc S
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 23.01.2018
Predmet:	Aged Amputation Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Biomarkers - blood Cholesterol, LDL - blood Down-Regulation Dyslipidemias - blood Dyslipidemias - diagnosis Dyslipidemias - drug therapy Dyslipidemias - mortality Female Humans Limb Salvage Male Middle Aged Peripheral Arterial Disease - blood Peripheral Arterial Disease - diagnosis Peripheral Arterial Disease - mortality Peripheral Arterial Disease - therapy Proprotein Convertase 9 - antagonists & inhibitors Proprotein Convertase 9 - metabolism Risk Factors Serine Proteinase Inhibitors - adverse effects Serine Proteinase Inhibitors - therapeutic use Time Factors Treatment Outcome atherosclerosis amputation cholesterol, LDL evolocumab peripheral arterial disease PCSK9 protein, human intermittent claudication
ISSN:	1524-4539, 1524-4539
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!